Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
1.225
+0.020 (1.66%)
Sep 30, 2026, 2:58 PM EDT - Market open
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 228 employees as of December 31, 2025. The number of employees decreased by 51 or -18.28% compared to the previous year.
Employees
228
Change (1Y)
-51
Growth (1Y)
-18.28%
Revenue / Employee
$643,075
Profits / Employee
-$985,702
Market Cap
27.78M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 228 | -51 | -18.28% |
| Dec 31, 2024 | 279 | -46 | -14.15% |
| Dec 31, 2023 | 325 | -60 | -15.58% |
| Dec 31, 2022 | 385 | -57 | -12.90% |
| Dec 31, 2021 | 442 | 10 | 2.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| aTyr Pharma | 60 |
| Evaxion | 46 |
| Quince Therapeutics | 38 |
| Kyntra Bio | 34 |
| ABVC BioPharma | 19 |
| Quantum BioPharma | 17 |
| Context Therapeutics | 15 |
KPTI News
- 19 days ago - Karyopharm, guarantors enter into forbearance agreement - TheFly
- 4 weeks ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Karyopharm submits sNDA to FDA for XPOVIO - TheFly
- 4 weeks ago - Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - PRNewsWire
- 6 weeks ago - Karyopharm reports Q2 EPS ($2.32) vs. ($4.32) last year - TheFly
- 6 weeks ago - Karyopharm Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - Karyopharm Therapeutics Earnings release: Q2 2026 - Filings
- 6 weeks ago - Karyopharm Therapeutics Quarterly report: Q2 2026 - Filings